Felice H Schnoll-Sussman, MD

Professor of Clinical Medicine

Gastroenterology and Hepatology (Medicine)

Contact & profiles

Appointments

Past Appointments

Associate Professor of Clinical Medicine
Medicine · 2013–2019
Assistant Professor of Clinical Medicine
Medicine · 2007–2013
Linda Horowitz Cancer Research Foundation Clinical Scholar in Gastroenterology
Medicine · 2006–2012

Show all 5

Centers

Education

Highlights

1
Proceedings (Baylor University. Medical Center) · 2025
CLChristine L. Frissora MFMelissa Frey FHFelice H Schnoll-Sussman
PMID: 40821478PMCID: PMC12351693DOISenior author1 citations

2 grants

Sub-PI
Cancer Immune-Interception for Lynch Syndrome
National Cancer Institute · 2021–2026 · via MD Anderson Cancer Center
R01CA257375-05
Co-I
Microbiota, Metabolites, and Colon Neoplasia
National Cancer Institute · 2021–2026 · via University of Connecticut
R01CA252045-02

Completed grants (1)

Sub-PI
The role of the microbiome and Notch signaling in esophageal adenocarcinoma
National Cancer Institute · 2021–2024 · via Columbia University
R01CA255298-03

1 study

PI
A Multicenter Randomized Trial of Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance (The SWAT-BE Study)
NA · CDx Diagnostics · OPEN TO ACCRUAL (as of 2023)
Barrett Esophagus; Barretts Esophagus With Dysplasia; Esophageal Adenocarcinoma
NCT05530343

Completed & closed trials (6)

PI
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
PHASE2 · MD Anderson Cancer Center · CLOSED TO ACCRUAL (as of 2026)
T Cells; Colorectal Cancer; Lynch Syndrome
NCT05411718
PI
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
Columbia University · IRB STUDY CLOSURE (as of 2025)
PI
A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
PHASE3 · Braintree Laboratories, INC · IRB STUDY CLOSURE (as of 2025)
Erosive Esophagitis
NCT05587309
PI
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
PHASE3 · Braintree Laboratories, INC · IRB STUDY CLOSURE (as of 2024)
Non-erosive Reflux Disease
NCT05587322
PI
The Oral Microbiome in Patients Undergoing Upper Endoscopy
Columbia University · IRB STUDY CLOSURE (as of 2021)
PI
Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis
PHASE3 · Adare Pharmaceuticals · IRB STUDY CLOSURE (as of 2021)
Eosinophilic Esophagitis
NCT04281108

Honoring Pioneers in Diversity in the Weill Cornell Community
April 24, 2026
On April 20, Weill Cornell Medicine awarded the Pioneers in Diversity Awards, recognizing commitment to diversity and inclusion through mentorship, service and advocacy.

The American Foregut Society

Braintree Laboratories, INC · Let's Win Pancreatic Cancer · Medtronic, Inc. · Phathom Pharmaceuticals Inc.